Details

Diagnostics to Pathogenomics of Sexually Transmitted Infections


Diagnostics to Pathogenomics of Sexually Transmitted Infections


1. Aufl.

von: Sunit Kumar Singh

170,99 €

Verlag: Wiley-Blackwell
Format: PDF
Veröffentl.: 19.09.2018
ISBN/EAN: 9781119380900
Sprache: englisch
Anzahl Seiten: 416

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

<p><b>Comprehensively explores sexually transmitted diseases, from epidemiology, causative pathogens, clinical impact, and immunology, to management strategies utilizing new strategies of genomics and next-generation diagnostic tools</b></p> <p>Sexually transmitted infections (STI) are very common worldwide. More than 20 different STIs have been identified, and about 19 million men and women are infected each year in the United States alone. This book looks at the complete picture of common STIs— how they form, evolve, and transmit, as well as how they can be treated and managed with modern techniques, medicines, and tools.</p> <p><i>Diagnostics to Pathogenomics of Sexually Transmitted Infections</i> runs the spectrum of discussion ranging from introduction of causative pathogen, their pathogenesis to epidemiology, immunology, to anatomy and physiology of human genitalia and management strategies. The book offers in-depth chapter coverage on effect of probiotics on reproductive health; mucosal immunity in sexually transmitted infections; the role of circumcision in preventing STIs; Human Immunodeficiency Virus (HIV); genital herpes; molluscum contagiosum; genital warts; chlaymydia trachomatis; donovanosis; gonorrhoea; treponematoses; genital mycoplasms; bacterial vaginosis; vulvovaginal candidiasis; chlaymydia; scabies; chancroid, yeast infections; and more.</p> <ul> <li>Comprehensively compiles most of the major sexually transmitted infections</li> <li>Presents updated information on clinical aspects of sexually transmitted infections</li> <li>Examines the priorities in pathogenesis of human sexually transmitted infections and discusses new strategies of genomics and next-generation diagnostic tools used for detection of such pathogens</li> <li>Explores the future of rapid molecular diagnostic techniques and the challenges posed in the diagnosis of human STIs</li> <li>Includes bench to bedside content that will appeal to both basic and clinical researchers</li> </ul> <p>By offering the latest knowledge about recent advances in sexually transmitted infections in an interdisciplinary fashion,<i> Diagnostics to Pathogenomics of Sexually Transmitted Infections</i> is the perfect book for virologists, microbiologists, infectious disease experts, vaccinologists, biomedical researchers, clinicians, pharmacologists, and public health specialists.</p>
<p>About the Editor xv</p> <p>Contributors xvii</p> <p>Preface xxi</p> <p><b>1 Mucosal Immunity in Sexually Transmitted Infections 1<br /></b><i>Jiri Mestecky and Michael W. Russell</i></p> <p>1.1 Introduction 1</p> <p>1.2 Innate Immunity in the Genital Tract 2</p> <p>1.2.1 Humoral Defense Factors in Female Secretions 2</p> <p>1.2.2 Innate Defense Factors in the Male Tract 4</p> <p>1.3 Immunoglobulins in Secretions of the Genital Tract 4</p> <p>1.3.1 Female Genital Tract Secretions 4</p> <p>1.3.2 Origin of Igs in Human Genital Tract Secretions 7</p> <p>1.3.3 Functions of Genital Tract Antibodies 8</p> <p>1.4 Cells of the Mucosal Immune System of the Genital Tract 10</p> <p>1.4.1 Epithelial Cells 10</p> <p>1.4.2 Immunoglobulin‐Producing Cells 10</p> <p>1.4.3 T Cells and Other Cell Types 11</p> <p>1.5 Induction of Immune Responses in the Genital Tract 12</p> <p>1.5.1 Induction of Humoral Immune Responses in Human Male Genital Tract Secretions 14</p> <p>1.5.2 Immune Responses in the Genital Tract after Infections 15</p> <p>1.5.2.1 Gonorrhea 15</p> <p>1.5.2.2 Chlamydia 15</p> <p>1.5.2.3 Human Immunodeficiency Virus (HIV) 16</p> <p>1.5.2.4 Human Papilloma Virus 16</p> <p>1.6 Concluding</p> <p>Remarks 17</p> <p>References 17</p> <p><b>2 The Role of Circumcision in Preventing Sexually Transmitted Infections 27<br /></b><i>Kourosh Afshar, Behnam Kazemi, and Andrew E. MacNeily</i></p> <p>2.1 Introduction 27</p> <p>2.2 Biological Mechanisms 27</p> <p>2.3 Methods of Circumcision 28</p> <p>2.4 Complications 28</p> <p>2.5 Role of MC in Transmission of HIV 29</p> <p>2.5.1 Male‐to‐Female Transmission 29</p> <p>2.5.2 Female‐to‐Male Transmission 29</p> <p>2.5.3 Male‐to‐Male Transmission 30</p> <p>2.6 Human Papilloma Virus (HPV) 30</p> <p>2.7 Nonulcerative STIs 31</p> <p>2.7.1 Gonorrhea 31</p> <p>2.7.2 Trichomonas Vaginalis (Tv) 32</p> <p>2.7.3 Chlamydia Trachomatis (Ct) 32</p> <p>2.8 Ulcerative STIs/Genital Ulcer Disease (GUD) 32</p> <p>2.8.1 Syphilis 33</p> <p>2.8.2 Chancroid 34</p> <p>2.9 Use of Male Circumcision as a Public Health Measure 34</p> <p>2.10 Female Genital Mutilation (FGM) 35</p> <p>References 36</p> <p><b>3 Effect of Probiotics on Reproductive Health 41<br /></b><i>Piotr Kochan, Magdalena Strus, and Piotr B. Heczko</i></p> <p>3.1 Introduction 41</p> <p>3.2 Definition of Probiotics 43</p> <p>3.3 Vaginal Microflora (Microbiota) 46</p> <p>3.4 Applications of Probiotics in Vaginal and Reproductive Health 49</p> <p>3.4.1 Vaginitis (Aerobic Vaginitis (AV), Bacterial Vaginosis (BV), and Vulvovaginal Candidiasis (VVC)) 50</p> <p>3.4.2 UTI 52</p> <p>3.4.3 Pregnancy 52</p> <p>3.4.4 Other Obstetrics and Gynecology (OB/GYN) Uses of Probiotics 53</p> <p>3.5 Conclusions 53</p> <p>References 54</p> <p><b>4 Human Immunodeficiency Virus (HIV) Infection 61<br /></b><i>Santosh Kumar Singh and Sunit K. Singh</i></p> <p>4.1 Introduction 61</p> <p>4.2 HIV Structure/Genome 62</p> <p>4.3 Routes of Transmission 64</p> <p>4.3.1 Sexual Transmission 64</p> <p>4.3.1.1 STDs and Sexual Transmission of HIV 64</p> <p>4.3.1.2 Vulnerability of Female Genital Tract for HIV Transmission 66</p> <p>4.3.2 Transmission by Contaminated Blood/Blood Product Transfusion 68</p> <p>4.3.3 Transmission by Sharing Syringe and Needles 68</p> <p>4.3.4 Transmission from Mother to Fetus or Newborn Babies 68</p> <p>4.3.5 Occupational Risk in Healthcare Workers 68</p> <p>4.4 Host Factors Influencing HIV Infectivity in Sexual Transmission 69</p> <p>4.4.1 Systemic Host Factors 69</p> <p>4.4.2 Local Host Factors 69</p> <p>4.5 Viral Factors Influencing HIV Infectivity in Sexual Transmission 70</p> <p>4.6 Mechanism of Pathogenesis 71</p> <p>4.7 Diagnosis of HIV Infections 72</p> <p>4.8 Therapeutics 73</p> <p>4.8.1 Antiretroviral Therapies (ARTs) 73</p> <p>4.8.2 Combinational ARTs 74</p> <p>4.9 Conclusion 74</p> <p>References 75</p> <p><b>5 Genital Herpes 83<br /></b><i>Andreas Sauerbrei</i></p> <p>5.1 Introduction 83</p> <p>5.2 Pathogen 83</p> <p>5.3 Epidemiology 84</p> <p>5.4 Pathogenesis and Immunity 84</p> <p>5.5 Clinical Features 86</p> <p>5.6 Diagnosis 87</p> <p>5.7 Treatment 90</p> <p>5.8 Prevention and Control 93</p> <p>5.9 Conclusion 94</p> <p>References 95</p> <p><b>6 Molluscum Contagiosum 101<br /></b><i>Tugba Kevser Uzuncakmak and Ayse Serap Karadag</i></p> <p>6.1 Introduction 101</p> <p>6.2 Epidemiology 101</p> <p>6.3 Molecular Pathogenesis 102</p> <p>6.4 Diagnosis 103</p> <p>6.5 Clinical Features 106</p> <p>6.6 Mode of Spread of Infections 107</p> <p>6.7 Treatment 107</p> <p>6.7.1 Treatment Options 108</p> <p>6.7.1.1 Watchful Waiting 108</p> <p>6.7.1.2 Procedure‐Based Treatments 109</p> <p>6.7.1.3 Chemical Agents 110</p> <p>6.7.1.4 Immune Modulators 111</p> <p>6.7.1.5 Antiviral Agents 112</p> <p>6.7.1.6 Immunocompromised Patients 112</p> <p>6.8 Conclusion 113</p> <p>References 113</p> <p><b>7 Genital Warts 119<br /></b><i>Filip Rob</i></p> <p>7.1 Introduction 119</p> <p>7.2 Human Papillomavirus 119</p> <p>7.2.1 Taxonomy 119</p> <p>7.2.2 Life Cycle 120</p> <p>7.2.3 Interaction with Immune System 120</p> <p>7.2.4 Transmission 120</p> <p>7.2.5 Clearance 120</p> <p>7.3 Epidemiology 121</p> <p>7.4 Risk and Protective Factors 121</p> <p>7.4.1 Risk Factors 121</p> <p>7.4.2 Protective Factors 122</p> <p>7.5 Clinical Features 122</p> <p>7.5.1 Physical Signs 122</p> <p>7.5.2 Symptoms 123</p> <p>7.6 Diagnostics 124</p> <p>7.6.1 Clinical Investigation 124</p> <p>7.6.2 3–5% Acetic Acid 124</p> <p>7.6.3 Histopathology 124</p> <p>7.6.4 HPV DNA Detection 125</p> <p>7.6.5 HPV Antibodies 125</p> <p>7.7 Differential Diagnosis 125</p> <p>7.8 Treatment 126</p> <p>7.8.1 Cryotherapy 126</p> <p>7.8.2 Laser Therapy (CO2 laser, Er:YAG laser) 127</p> <p>7.8.3 Electrocautery 127</p> <p>7.8.4 Surgical Excision 127</p> <p>7.8.5 Trichloracetic Acid (80–90% solution) 127</p> <p>7.8.6 Podophyllotoxin (0.05% solution or 0.15% gel) 127</p> <p>7.8.7 Imiquimod (3.75% or 5% cream) 127</p> <p>7.8.8 Sinecatechins (10% or 15% ointment) 129</p> <p>7.9 Specific Groups 129</p> <p>7.9.1 Immunocompromised Patients 129</p> <p>7.9.2 Pregnant Women 129</p> <p>7.9.3 Children 129</p> <p>7.10 HPV Vaccination 130</p> <p>References 131</p> <p><b>8 Chlamydia Trachomatis Urogenital Infections: Epidemiology, Clinical Presentations, and Pathogenesis 135<br /></b><i>Charles W. Armitage, Alison J. Carey, Danica K. Hickey, and Kenneth W. Beagley</i></p> <p>8.1 Introduction 135</p> <p>8.2 Epidemiology 135</p> <p>8.3 Chlamydial Biology 136</p> <p>8.3.1 The Attachment and Entry of Chlamydial EBs 136</p> <p>8.3.2 The Chlamydial Inclusion 137</p> <p>8.3.3 Chlamydial Replication and Persistence 137</p> <p>8.4 Clinical Features 138</p> <p>8.4.1 Urogenital Tract Infections 139</p> <p>8.4.2 Female Urogenital Tract 139</p> <p>8.4.3 Infection and Pregnancy 141</p> <p>8.4.4 Male Urogenital Tract 142</p> <p>8.4.5 Anorectal Tract Infections 143</p> <p>8.4.6 Gastrointestinal Chlamydial Infections and Persistence 144</p> <p>8.4.7 Lymphogranuloma Venereum 144</p> <p>8.5 Pathogenesis of Chlamydial Infections 145</p> <p>8.5.1 Pathogenesis of Female Genital Tract Chlamydial Infections 145</p> <p>8.5.2 Lower FRT Pathogenesis 146</p> <p>8.5.3 Upper FRT Pathogenesis 146</p> <p>8.5.4 Pathogenesis of Male Urogenital Tract 148</p> <p>8.5.5 Chlamydial Urethritis and Prostatitis 148</p> <p>8.5.6 Chlamydial Infections of the Upper MRT 148</p> <p>8.5.7 Chlamydial Epididymitis 149</p> <p>8.5.8 Chlamydial Orchitis 149</p> <p>8.6 Diagnosis and Treatment 150</p> <p>8.7 Prevention and Control 151</p> <p>8.8 Conclusion 152</p> <p>References 153</p> <p><b>9 Donovanosis 167<br /></b><i>Sarita Martins De Carvalho Bezerra, Marcio Martins Lobo Jardim, and Juliana Uchiyama</i></p> <p>9.1 Introduction 167</p> <p>9.2 Epidemiology 168</p> <p>9.3 Pathology 168</p> <p>9.4 Incubation Period 169</p> <p>9.5 Clinical Pictures 170</p> <p>9.6 Sites of Involvement 174</p> <p>9.7 Complications and Sequelae 175</p> <p>9.8 Diagnosis 175</p> <p>9.9 Differential Diagnosis 176</p> <p>9.10 Treatment 176</p> <p>9.11 Prevention and Control 177</p> <p>9.12 Disease Control and Prevention 178</p> <p>References 178</p> <p><b>10 Gonorrhea 181 <br /></b><i>María Teresa Pérez‐Gracia and Beatriz Suay‐García</i></p> <p>10.1 Introduction 181</p> <p>10.2 Pathogen 182</p> <p>10.2.1 Morphology 182</p> <p>10.2.2 Virulence Factors 183</p> <p>10.2.2.1 Type IV Pili (Tfp) 183</p> <p>10.2.2.2 Por Proteins 183</p> <p>10.2.2.3 Opacity Proteins (Opa) 184</p> <p>10.2.2.4 Rmp Proteins 184</p> <p>10.2.2.5 Lipooligosaccharide (LOS) 184</p> <p>10.2.2.6 IgA Protease 185</p> <p>10.2.3 Physiology 185</p> <p>10.2.4 Genome 185</p> <p>10.3 Pathogenesis and Immunity 185</p> <p>10.4 Epidemiology 186</p> <p>10.5 Clinical Features 188</p> <p>10.5.1 Gonococcal Infection in Men 188</p> <p>10.5.2 Gonococcal Infection in Women 188</p> <p>10.5.3 Extragenital Locations 188</p> <p>10.6 Diagnosis 189</p> <p>10.6.1 Samples 189</p> <p>10.6.2 Staining 191</p> <p>10.6.3 Culture 191</p> <p>10.6.4 Identification 193</p> <p>10.6.5 Neisseria gonorrhoeae Genotyping 193</p> <p>10.6.6 Nucleic Acid Amplification Tests (NAATs) 197</p> <p>10.7 Treatment 198</p> <p>10.8 Prevention and Control 200</p> <p>10.9 Conclusion 202</p> <p>References 202</p> <p><b>11 Sexually Transmitted Treponematoses 211<br /></b><i>Lenka Mikalová and David Šmajs</i></p> <p>11.1 Introduction 211</p> <p>11.2 Genetics of TPA and TEN Strains 212</p> <p>11.3 Virulence Factors of Syphilis and Bejel 214</p> <p>11.4 Diagnostics of Syphilis and Bejel 215</p> <p>11.5 Treatment of Syphilis and Bejel 217</p> <p>11.6 Molecular Typing of Syphilis and Bejel Treponemes 220</p> <p>11.7 Vaccine Development for Syphilis and Bejel 222</p> <p>References 223</p> <p><b>12 Genital Mycoplasmas 233<br /></b><i>Suncanica Ljubin‐Sternak</i></p> <p>12.1 Introduction 233</p> <p>12.2 Biology 234</p> <p>12.3 Pathogenesis 235</p> <p>12.3.1 Adhesion Proteins 236</p> <p>12.3.2 Antigenic Variation 236</p> <p>12.3.3 Production of Enzymes 236</p> <p>12.3.4 Facultative Intracellular Localization 237</p> <p>12.3.5 Capacity to Induce Host Immune Response 237</p> <p>12.4 Epidemiology 237</p> <p>12.5 Clinical Presentation 238</p> <p>12.5.1 Urogenital Infections in Women 238</p> <p>12.5.1.1 Bacterial Vaginosis 238</p> <p>12.5.1.2 Cervicitis 239</p> <p>12.5.1.3 Pelvic Inflammatory Disease (PID) and Its Sequalae 239</p> <p>12.5.1.4 Infections in Pregnancy 240</p> <p>12.5.2 Urogenital Infections in Men 241</p> <p>12.5.2.1 Nongonococcal Urethritis (NGU) 241</p> <p>12.5.2.2 Epididymitis and Prostatitis 241</p> <p>12.5.2.3 Infertility 241</p> <p>12.5.3 Rare Manifestations and Clinical Features in Immunocompromised Persons 242</p> <p>12.5.3.1 Urinary Calculi 242</p> <p>12.5.3.2 Systemic Infection and Arthritis 242</p> <p>12.5.3.3 Infection in Immunocompromised Patients 242</p> <p>12.6 Laboratory Diagnosis 243</p> <p>12.6.1 Specimen Collection 243</p> <p>12.6.2 Culture Methods 243</p> <p>12.6.3 Molecular Methods 245</p> <p>12.6.4 Serology 246</p> <p>12.7 Treatment 247</p> <p>12.8 Prevention and Control 248</p> <p>References 249</p> <p><b>13 Bacterial Vaginosis 257<br /></b><i>Aliona Rosca and Nuno Cerca</i></p> <p>13.1 Introduction 257</p> <p>13.2 Implication of G. vaginalis in Bacterial Vaginosis 258</p> <p>13.3 Epidemiology and Risk Factors 260</p> <p>13.4 Pathogenesis and Immunity 261</p> <p>13.5 Clinical Features 263</p> <p>13.6 Diagnosis 263</p> <p>13.7 Treatment 266</p> <p>13.8 Conclusions 268</p> <p>References 268</p> <p><b>14 Chancroid 277<br /></b><i>Margaret E. Bauer and Diane M. Janowicz</i></p> <p>14.1 Introduction 277</p> <p>14.2 Epidemiology of Chancroid and H. ducreyi 277</p> <p>14.3 Clinical Features 278</p> <p>14.4 The Pathogen 279</p> <p>14.5 Pathogenesis and Immunity 280</p> <p>14.5.1 Overview of Pathogenesis 280</p> <p>14.5.2 Virulence Mechanisms 280</p> <p>14.5.3 Regulation of Virulence 282</p> <p>14.5.4 Immune Response 283</p> <p>14.6 Diagnosis, Treatment, and Prevention 284</p> <p>14.7 Chronic Limb Ulcers Caused by H. ducreyi 285</p> <p>14.8 Conclusions 286</p> <p>References 287</p> <p><b>15 Vulvovaginal Candidosis 293<br /></b><i>Gilbert G.G. Donders, Katerina S. Ruban, Gert Bellen, and Sivtrigaile Grinceviciene</i></p> <p>15.1 Introduction 293</p> <p>15.2 Etiology 293</p> <p>15.2.1 Pathogens 293</p> <p>15.2.2 Morphology 294</p> <p>15.3 Epidemiology 294</p> <p>15.3.1 Prevalence 294</p> <p>15.3.1.1 Asymptomatic Colonization 294</p> <p>15.3.1.2 Symptomatic Infection 295</p> <p>15.3.2 Risk Factors 298</p> <p>15.3.3 Sexual Transmission 298</p> <p>15.3.4 Young and Elderly Women 298</p> <p>15.4 Pathogenesis and Immunity 300</p> <p>15.4.1 Hormones 300</p> <p>15.4.2 Pregnancy 300</p> <p>15.4.3 Impaired Glucose Tolerance 301</p> <p>15.4.4 Genetic Predisposition 301</p> <p>15.4.4.1 STAT1 Gain of Function Mutations 302</p> <p>15.4.4.2 CARD9 302</p> <p>15.4.4.3 AIRE Mutation 302</p> <p>15.4.4.4 NALP3/CIAS1 304</p> <p>15.4.4.5 Interleukin-4 304</p> <p>15.4.4.6 Dectin-1 304</p> <p>15.4.4.7 Mannose‐Binding Lectin (MBL) 304</p> <p>15.4.5 Other Factors Affecting Pathogenesis 305</p> <p>15.5 Symptoms and Signs 305</p> <p>15.5.1 Acute/Episodic Infection 305</p> <p>15.5.2 Recurrent Vulvovaginal Candidosis 306</p> <p>15.6 Diagnosis and Differential Diagnosis 306</p> <p>15.6.1 Clinical Signs 306</p> <p>15.6.2 Clinical Examination 306</p> <p>15.6.3 Wet Mount Microscopy 307</p> <p>15.6.4 Vaginal pH 309</p> <p>15.6.5 Vaginal Mycological Culture 310</p> <p>15.6.6 Molecular Biology 310</p> <p>15.6.7 Histology 310</p> <p>15.6.8 Differential Diagnosis 310</p> <p>15.7 Treatment 311</p> <p>15.7.1 General Principles of Treatment 311</p> <p>15.7.2 Treatment of Uncomplicated Acute Infection 311</p> <p>15.7.3 Treatment of Complicated Acute Infection 312</p> <p>15.7.3.1 Severe Symptoms, C. albicans Vulvovaginitis 314</p> <p>15.7.3.2 Non‐Albicans Candida Infection 314</p> <p>15.7.3.3 Poorly Controlled Diabetes, Immune Suppression 315</p> <p>15.7.3.4 Pregnancy and Breastfeeding 315</p> <p>15.7.4 Recurrent Vulvovaginal Candidiasis (RVVC) 316</p> <p>15.7.4.1 Azole‐Resistant C. albicans 317</p> <p>15.7.4.2 Elimination of Risk Factors of Recurrence in RVVC Patients 317</p> <p>15.7.4.3 Underlying Reasons for Failing Maintenance Therapy 318</p> <p>References 319</p> <p><b>16 Tinea Cruris 329<br /></b><i>Anuradha Bishnoi and Rahul Mahajan</i></p> <p>16.1 Introduction 329</p> <p>16.2 Etiology and Epidemiology 330</p> <p>16.3 Tinea Cruris as a Sexually Transmitted Infection (STI) 331</p> <p>16.4 Transmission 331</p> <p>16.5 Pathogenesis 332</p> <p>16.5.1 Environmental Factors 332</p> <p>16.5.2 Agent Factors 332</p> <p>16.5.3 Host Factors 332</p> <p>16.5.4 Host Immune Response 333</p> <p>16.5.5 Clinical Features 333</p> <p>16.5.6 Variants 335</p> <p>16.5.6.1 Tinea incognito 335</p> <p>16.5.6.2 Vesico‐Bullous Tinea Cruris 335</p> <p>16.5.6.3 White Paint Dots and Pseudomembranous Tinea 335</p> <p>16.6 Differential Diagnoses 336</p> <p>16.6.1 Candidiasis 336</p> <p>16.6.2 Erythrasma 336</p> <p>16.6.3 Hyperpigmented Pityriasis Versicolor 336</p> <p>16.7 Laboratory Diagnosis 336</p> <p>16.7.1 Direct Examination 336</p> <p>16.7.2 Culture 337</p> <p>16.7.3 Nucleic Acid Amplification Tests 337</p> <p>16.8 Treatment of Tinea Cruris and Genitalis 337</p> <p>16.8.1 Topicals 337</p> <p>16.8.2 Systemic 337</p> <p>16.8.3 Recalcitrant/Resistant Tinea: Pathomechanisms and Treatment 338</p> <p>16.8.4 General Measures to Prevent Tinea Cruris 338</p> <p>16.9 Conclusion 338</p> <p>Acknowledgments 339</p> <p>References 339</p> <p><b>17 Trichomonas Vaginalis 341<br /></b><i>Barbara Van Der Pol</i></p> <p>17.1 Introduction 341</p> <p>17.2 Epidemiology of T. vaginalis 342</p> <p>17.3 HIV and Trichomonas 344</p> <p>17.4 Biology and Pathogenesis of T. vaginalis 345</p> <p>17.5 Clinical Features of T. vaginalis Infection 346</p> <p>17.6 Diagnosis of T. vaginalis 348</p> <p>17.6.1 Laboratory Diagnosis 349</p> <p>17.7 Treatment of T. vaginalis 350</p> <p>17.8 Conclusion 351</p> <p>References 351</p> <p><b>18 Scabies 357<br /></b><i>Giuseppe Micali, Giorgia Giuffrida, and Francesco Lacarrubba</i></p> <p>18.1 Introduction 357</p> <p>18.2 Epidemiology 357</p> <p>18.3 Etiopathogenesis 358</p> <p>18.4 Clinical Features 359</p> <p>18.5 Diagnosis 363</p> <p>18.5.1 Microscopy 363</p> <p>18.5.2 Dermatoscopy/Videodermatoscopy 363</p> <p>18.5.3 Histopathology 365</p> <p>18.5.4 Other Diagnostic Procedures 366</p> <p>18.6 Treatment 366</p> <p>18.6.1 Topical Agents 366</p> <p>18.6.2 Oral Agents 367</p> <p>18.6.3 Treatment for Crusted Scabies 367</p> <p>18.7 Prevention and Control 368</p> <p>18.8 Conclusion 368</p> <p>References 368</p> <p>Index 373</p>
<p><b>About the Editor</b> <p><b>Dr. Sunit K. Singh</b> is Professor of Molecular Immunology and Head of the Molecular Biology Unit at the Faculty of Medicine, Institute of Medical Sciences (IMS), Banaras Hindu University (BHU), Varanasi, India.
<p><b>Comprehensively explores sexually transmitted diseases, from epidemiology, causative pathogens, clinical impact, and immunology, to management strategies utilizing new strategies of genomics and next-generation diagnostic tools</b> <p>Sexually transmitted infections (STIs) are very common worldwide. More than 20 different STIs have been identified, and about 19 million men and women are infected each year in the United States alone. This book looks at the complete picture of common STIs— how they form, evolve, and transmit, as well as how they can be treated and managed with modern techniques, medicines, and tools. <p><i>Diagnostics to Pathogenomics of Sexually Transmitted Infections</i>??runs the spectrum of discussion ranging from introduction of causative pathogen, their pathogenesis to epidemiology, immunology, to anatomy and physiology of human genitalia and management strategies. The book offers in-depth chapter coverage on the effects of probiotics on reproductive health; mucosal immunity in sexually transmitted infections; the role of circumcision in preventing STIs; Human Immunodeficiency Virus (HIV); genital herpes; molluscum contagiosum; genital warts; chlaymydia trachomatis; donovanosis; gonorrhoea; treponematoses; genital mycoplasms; bacterial vaginosis; vulvovaginal candidiasis; chlaymydia; scabies; chancroid, yeast infections; and more. <ul> <li>Comprehensively compiles most of the major sexually transmitted infections</li> <li>Presents updated information on clinical aspects of sexually transmitted infections</li> <li>Examines the priorities in pathogenesis of human sexually transmitted infections and discusses new strategies of genomics and next-generation diagnostic tools used for detection of such pathogens</li> <li>Explores the future of rapid molecular diagnostic techniques and the challenges posed in the diagnosis of human STIs</li> <li>Includes bench to bedside content that will appeal to both basic and clinical researchers</li> </ul> <p>By offering the latest knowledge about recent advances in sexually transmitted infections in an interdisciplinary fashion,<i>??Diagnostics to Pathogenomics of Sexually Transmitted Infections</i>??is the perfect book for virologists, microbiologists, infectious disease experts, vaccinologists, biomedical researchers, clinicians, pharmacologists, and public health specialists.

Diese Produkte könnten Sie auch interessieren:

The Biology of Echinostomes
The Biology of Echinostomes
von: Bernard Fried, Rafael Toledo
PDF ebook
149,79 €
Antibiotic Policies
Antibiotic Policies
von: Ian M. Gould, Jos W.M. van der Meer
PDF ebook
213,99 €
Tropical and Parasitic Infections in the Intensive Care Unit
Tropical and Parasitic Infections in the Intensive Care Unit
von: Charles Feldman, George A. Sarosi
PDF ebook
149,79 €